We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK and ViiV Healthcare Use $130 Million Priority Review Voucher to Expedite HIV Therapy
GSK and ViiV Healthcare Use $130 Million Priority Review Voucher to Expedite HIV Therapy
GlaxoSmithKline and ViiV Healthcare redeemed a priority review voucher for their application for a single-tablet antiretroviral regimen of Tivicay (dolutegravir) and Edurant (rilpivirine) for maintenance treatment of HIV-1 infections. The voucher allows for an expedited six-month review — cutting four months from the standard review.
